Nonalcoholic fatty liver disease and the renin-angiotensin system blockers in the patients with chronic kidney disease;Nicht-alkoholische Fettleber und Blocker des Renin-Angiotensin Systems bei Patienten mit chronischer Nierenerkrankung

Wiener Klinische Wochenschrift

Volumn 127, Issue 9-10, 2015, Pages 355-362

  Orlic, Lidija ^a   Mikolasevic, Ivana ^a   Lukenda, Vesna ^b   Anic, Kata ^c   Jelic, Ita ^a   Racki, Sanjin ^a  

^a KBC RIJEKA   (Croatia)

^b DR JOSIP BEN EVI GENERAL HOSPITAL   (Croatia)

^c Infectious Disease Clinic   (Croatia)

Author keywords

Chronic kidney disease; Non invasive screening; Nonalcoholic fatty liver disease (NAFLD); Renin angiotensin aldosteron system; Transient elastography

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; TELMISARTAN; TRANDOLAPRIL;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CROSS-SECTIONAL STUDY; ELASTOGRAPHY; END STAGE RENAL DISEASE; FATTY LIVER; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RIGIDITY; AGED; COHORT ANALYSIS; DRUG EFFECTS; KIDNEY FAILURE, CHRONIC; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; ELASTICITY IMAGING TECHNIQUES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84939418125     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-014-0661-y     Document Type: Article

References (28)

1. Cervera-Lizardi J, Zapata-Aguilar D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol. 2009;8(1):S40–3.
2. Kim CH, Younossi ZM. Non alcoholic fatty liver disease: a manifestation of metabolic syndrome. Cleve Clin J Med. 2008;75:721–8.
3. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Disease, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–23.
4. Mikolasevic I, Racki S, Zaputovic l, Lukenda V, Milic S, Orlic L. Nonalcoholic fatty liver disease (NAFLD); a new risk factor for adverse cardiovascular events in dialysis patients. Med Hypothesis. 2014;82:205–8.
5. Sasso M, Beaugrand M, dee Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36(11):1825–35.
6. Wong GLH. Transient elastography: kill two birds with one stone? Word J Hepatol. 2013;5:264–74.
7. Mikolasevic I, Racki S, Lukenda V, Pavletic-Persic M, Milic S, Orlic L. Non-alcoholic fatty liver disease; a part of the metabolic syndrome in the renal transplant recipients and possible cause of an allograft dysfunction. Med Hypothesis. 2014;82:36–9.
8. Targher G, Bertolini L, Rodella S, et al. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol. 2010;5:2166–71.
9. Hamad AA, Khalil AA, Connolly V, et al. Relationship between non-alcoholic fatty liver disease and kidney function: a communication between two organs that needs further exploration. Arab J Gastroenterol. 2012;13:161–5.
10. Targher G, Chonchol M, Zoppini G, et al. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link? J Hepatol. 2011;54:1020–9.
11. Mikolasevic I, Racki S, Bubic I, Jelic I, Stimac D, Orlic L. Chronic kidney disease and nonalcoholic fatty liver disease proven by transient elastography. Kidney Blood Press Res. 2013;37:305–10.
12. Paschos P, Tziomalos K. Nonalcoholic fatty liver disease and the rennin-angiotensin system: implications for treatment. World J Hepatol. 2012;4:327–31.
13. Abbas G, Silveira MG, Lindor KD. Hepatic fibrosis and the rennin-angiotensin system. Am J Ther. 2011;18:e202–8.
14. Tobli JE, Munoz MC, Cao G, Mella J, Pereyra L, Mastai R. ACE inhibitors and AT1 blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity (Silver Spring). 2008;16:770–6.
15. Pereira RM, dos Santos RAS, da Costa Dias FL, Teixeira MM, Simoes e Silva AC. Renin-angiotensin system in the pathogenesis of liver fibrosis. World J Gastroenterol. 2009;15:2579–86.
16. Hirata T, Tomita K, Kawai T, Yokoyama H, Shimada A, Kikuchi M, et al. Effect of telmisartan for treatment of nonalcoholic fatty liver disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). Int J Endocrinol. 2013;2013 (Article ID 587140).
17. Grace JA, Herath CB, Mak KY, Burrell LM, Angus PW. Update on new aspects of the rennin-angiotensin system in liver disease: clinical implications and new therapeutic options. Clin Sci. 2012;123:225–39.
18. Toblli JE, De Rosa G, Rivas C, et al. Cardiovascular protective role of a low-dose antihypertensive combination in obese Zucker rats. J Hypertens. 2003;21:611–20.
19. Sun Y, Zhang J, Zhang JQ, Ramires FJ. Local angiotensin II and transforming growth factor – beta1 in renal fibrosis of rats. Hypertension. 2000;35:1078–84.
20. Bataller R, Sancho-Bru P, Gines P, Brenner DA. Liver fibrogenesis: a new role for the renin-angiotenzin system. Antioxid Redox Signal. 2005;7:1346–55.
21. Georgescu EF. Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option? Adv Ther 2008;25:1141–74.
22. Libertato Oliveira IR Lopes Almeida EP Cavalcante Mattos MAG, et al. Liver enzymes in patients with chronic kidney disease undergoing peritoneal dialysis and hemodialysis. Clinics. 2012;67(2):131–4.
23. Ono K, Ono T, Matsumata T. The pathogenesis of decreased aspartate amino-transferase and alanine aminotransferase activity in the plasma of hemodialysis patients: the role of vitamin B6 deficiency. Clin Nephrol. 1995;43:405–8.
24. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotrasnferase levels. Ann Int Med. 2002;137:1–9.
25. Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114:842–5.
26. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33:525–40.
27. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191:235–40.
28. Gaia S, Carenzi S, Barilli AL, et al. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J Hepatol. 2011;54:64–71.